4SC AG Strengthens Patent Protection for its Hedgehog/GLI Signaling Inhibitor 4SC-208
January 22, 2018 at 12:00 pm IST
4SC AG announced that composition of matter patents for a group of molecules including 4SC-208, an orally-available hedgehog/GLI signaling inhibitor in formal preclinical testing for the treatment of Hedgehog-driven cancers, were granted in further geographic regions. The patents now not only provide 4SC with market exclusivity until 2033 in the U.S. but also in China, Japan, Singapore, Australia and New Zealand.